Abstract
Cancer is a genetic disease which progresses from benign to malignant stages through the steady acquisition of genomic mutations in key cell-regulatory genes, namely oncogenes, tumor-suppressors, and stability genes. In many ways cancer is considered as a disease of de-regulated signal transduction. Oncogenic mutations frequently lead to overexpression and/or constitutive activation of signal transduction components, allowing cancer cells to override the controlling mechanisms of signalling networks and acquire the cancer-associated traits known as the six hallmarks of cancer. The molecular chaperone HSP90 is viewed as a key player in the subversion of normal cells toward transformation, since many of its client proteins are linked to signalling pathways, commonly de-regulated during tumorigenesis. Consequently, over the past years HSP90 has emerged as a promising and exciting target for the development of cancer chemotherapeutics and already several HSP90 inhibitors are under clinical evaluation. Recently, a pool of HSP90 was identified at the cell surface, where it was shown to be involved in signalling pathways leading to cell motility and invasion. Independent studies suggest that surface HSP90 could be a promising target for the development of effective anti-metastatic strategies. Thus a need for the development of novel cell-impermeable HSP90 inhibitors is emerging.
Current Signal Transduction Therapy
Title: Extracellular HSP90: An Emerging Target for Cancer Therapy
Volume: 4 Issue: 1
Author(s): Katerina Sidera and Evangelia Patsavoudi
Affiliation:
Abstract: Cancer is a genetic disease which progresses from benign to malignant stages through the steady acquisition of genomic mutations in key cell-regulatory genes, namely oncogenes, tumor-suppressors, and stability genes. In many ways cancer is considered as a disease of de-regulated signal transduction. Oncogenic mutations frequently lead to overexpression and/or constitutive activation of signal transduction components, allowing cancer cells to override the controlling mechanisms of signalling networks and acquire the cancer-associated traits known as the six hallmarks of cancer. The molecular chaperone HSP90 is viewed as a key player in the subversion of normal cells toward transformation, since many of its client proteins are linked to signalling pathways, commonly de-regulated during tumorigenesis. Consequently, over the past years HSP90 has emerged as a promising and exciting target for the development of cancer chemotherapeutics and already several HSP90 inhibitors are under clinical evaluation. Recently, a pool of HSP90 was identified at the cell surface, where it was shown to be involved in signalling pathways leading to cell motility and invasion. Independent studies suggest that surface HSP90 could be a promising target for the development of effective anti-metastatic strategies. Thus a need for the development of novel cell-impermeable HSP90 inhibitors is emerging.
Export Options
About this article
Cite this article as:
Sidera Katerina and Patsavoudi Evangelia, Extracellular HSP90: An Emerging Target for Cancer Therapy, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048739
DOI https://dx.doi.org/10.2174/157436209787048739 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Activity of New Haloalkyl Camptothecin Esters against Human Cancer Cell Lines and Human Tumor Xenografts Grown in Nude Mice
Anti-Cancer Agents in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Critical Functions of lncRNA DGCR5 in Cancers of the Digestive System
Current Pharmaceutical Design Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design Natural Product Gossypol and its Derivatives in Precision Cancer Medicine
Current Medicinal Chemistry Retracted: Potential Health Benefits of Broccoli- A Chemico-Biological Overview
Mini-Reviews in Medicinal Chemistry Postmenopausal Hormone Therapy
Current Women`s Health Reviews Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry A Hybrid Discrete Imperialist Competition Algorithm for Gene Selection for Microarray Data
Current Proteomics Bladder Cancer: Innovative Approaches Beyond the Diagnosis
Current Medicinal Chemistry Human Galectin-1 in Multiple Cancers: A Privileged Molecular Target in Oncology
Mini-Reviews in Medicinal Chemistry Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Soluble Guanylate Cyclase: A New Therapeutic Target for Fibrotic Diseases
Current Medicinal Chemistry The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Immunotherapy in Breast Cancer- Paving New Roads?
Current Molecular Pharmacology The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Effect of Passion Fruit (Passiflora edulis f. flavicarpa deg.) Peel Flour on the Prognosis of Acute Pancreatitis after Overnutrition During Lactation
The Natural Products Journal